New FDA peptide advisers could benefit from their own rulings

The Food and Drug Administration recently announced the addition of eight new panelists to a committee tasked with advising the agency on the regulation of compounding pharmacies manufacturing certain peptides. Among the new members are individuals with ties to businesses that promote and prescribe peptides, raising concerns about potential conflicts of interest.

One notable addition to the committee is pharmacist and Tennessee state senator Bobby Harshbarger, who is the son of U.S. Rep. Diana Harshbarger, also a pharmacist. Rep. Harshbarger has actively advocated for the FDA to relax regulations on peptides, a stance that has drawn criticism from experts in the field. Paul Knoepfler, a professor at UC Davis School of Medicine, expressed apprehension about the committee composition, noting that several members have been associated with selling unproven treatments like stem cells and peptides.

These developments have sparked speculation about the committee’s direction and whether it will prioritize the interests of the peptide industry over public health concerns. Some observers, including Knoepfler, fear that the committee may be influenced by individuals with vested interests in promoting unproven peptides, potentially compromising the agency’s ability to regulate these products effectively.

The controversy surrounding the new panelists underscores the complex interplay between politics, industry influence, and public health within the FDA. As the committee prepares to address key regulatory issues related to peptides, stakeholders will be closely monitoring the decisions and recommendations put forth by its members.

For more in-depth analysis and exclusive content on this topic, readers can subscribe to STAT+ to access premium articles, newsletters, and news alerts. Stay informed on the latest developments in FDA regulation and the evolving landscape of peptide therapies by subscribing to STAT+ today.